A FLEXIBLE SENSITIVITY ANALYSIS APPROACH FOR UNMEASURED CONFOUNDING WITH MULTIPLE TREATMENTS AND A BINARY OUTCOME WITH APPLICATION TO SEER-MEDICARE LUNG CANCER DATA

被引:0
|
作者
Hu, Liangyuan [1 ]
Zou, Jungang [2 ]
Gu, Chenyang [3 ]
Ji, Jiayi [4 ]
Lopez, Michael [5 ]
Kale, Minal [6 ]
机构
[1] Rutgers State Univ, Dept Biostat & Epidemiol, New Brunswick, NJ 08854 USA
[2] Columbia Univ, Dept Biostat, New York, NY 10027 USA
[3] Brown Univ, Dept Biostat, Providence, RI 02912 USA
[4] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA
[5] Skidmore Coll, Dept Math, Saratoga Springs, NY 12866 USA
[6] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
来源
ANNALS OF APPLIED STATISTICS | 2022年 / 16卷 / 02期
关键词
Causal inference; ignorability assumption; observational data; Bayesian inference; nested multiple imputation; IMPUTATION; MODEL;
D O I
10.1214/21-AOAS1530
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
In the absence of a randomized experiment, a key assumption for drawing causal inference about treatment effects is the ignorable treatment assignment. Violations of the ignorability assumption may lead to biased treatment effect estimates. Sensitivity analysis helps gauge how causal conclusions will be altered in response to the potential magnitude of departure from the ignorability assumption. However, sensitivity analysis approaches for unmeasured confounding in the context of multiple treatments and binary outcomes are scarce. We propose a flexible Monte Carlo sensitivity analysis approach for causal inference in such settings. We first derive the general form of the bias introduced by unmeasured confounding, with emphasis on theoretical properties uniquely relevant to multiple treatments. We then propose methods to encode the impact of unmeasured confounding on potential outcomes and adjust the estimates of causal effects in which the presumed unmeasured confounding is removed. Our proposed methods embed nested multiple imputation within the Bayesian framework, which allow for seamless integration of the uncertainty about the values of the sensitivity parameters and the sampling variability as well as use of the Bayesian Additive Regression Trees for modeling flexibility. Expansive simulations validate our methods and gain insight into sensitivity analysis with multiple treatments. We use the SEER-Medicare data to demonstrate sensitivity analysis using three treatments for early stage nonsmall cell lung cancer. The methods developed in this work are readily available in the R package SAMTx.
引用
收藏
页码:1014 / 1037
页数:24
相关论文
共 50 条
  • [21] Diabetes Treatments and Risks of Adverse Breast Cancer Outcomes among Early-Stage Breast Cancer Patients: A SEER-Medicare Analysis
    Chen, Lu
    Chubak, Jessica
    Boudreau, Denise M.
    Barlow, William E.
    Weiss, Noel S.
    Li, Christopher I.
    CANCER RESEARCH, 2017, 77 (21) : 6033 - 6041
  • [22] Androgen Deprivation Therapy for Prostate Cancer Associated with Improved Survival in Non Small Cell Lung Cancer: A SEER-MEDICARE Analysis
    Kumar, Mukesh
    Ragin, Camille
    Zhang, Chao
    Chen, Zhengjia
    Han, Erica J.
    Ernani, Vinicius
    Behera, Madhusmita
    Steuer, Conor
    Saba, Nabil
    Shin, Doug
    Belani, Chandra P.
    Khuri, Fadlo
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S545 - S545
  • [23] Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data
    Michels, Kara A.
    McNeel, Timothy S.
    Trabert, Britton
    GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 294 - 300
  • [24] Two-stage residual inclusion for survival data and competing risksAn instrumental variable approach with application to SEER-Medicare linked data
    Ying, Andrew
    Xu, Ronghui
    Murphy, James
    STATISTICS IN MEDICINE, 2019, 38 (10) : 1775 - 1801
  • [25] Patient and county level determinants of surgical treatment for non-small cell lung cancer: A SEER-Medicare analysis
    Odahowski, Cassie Lewis
    Alberg, Anthony J.
    Schootman, Mario
    Zhang, Jiajia
    Eberth, Jan M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [26] How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis
    Khan, Saad A.
    Pruitt, Sandi L.
    Xuan, Lei
    Makris, Una
    Gerber, David E.
    LUNG CANCER, 2018, 115 : 97 - 102
  • [27] Second Malignancies Among Elderly Multiple Myeloma Patients Exposed to Bortezomib and Other Treatments: An Analysis of the US SEER-Medicare Linked Database
    Gifkins, Dina
    McAuliffe, Megan
    Matcho, Amy
    Porter, Jane
    Chavers, Scott
    Ponsillo, Maria
    King, Jay
    Desai, Avinash
    Cakana, Andrew
    Esseltine, Dixie-Lee
    BLOOD, 2011, 118 (21) : 1700 - 1700
  • [28] Anti-dementia and anti-hyperlipidemic medication use at end of life in elderly lung cancer patients: Analysis of SEER-Medicare data.
    Kim, Min Ji
    Duan, Zhigang
    Zhao, Hui
    Holmes, Holly Michelle
    Manzano, Joanna -Grace Mayo
    Giordano, Sharon Hermes
    Suarez-Almazor, Maria E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Mortality Differs by Stage for Right- vs Left-Sided Colon Cancer: Analysis of SEER-Medicare Data
    Weiss, Jennifer
    Pfau, Patrick
    O'Connor, Erin S.
    King, Jonathan
    LoConte, Noelle K.
    Kennedy, Gregory A.
    Smith, Maureen A.
    GASTROENTEROLOGY, 2011, 140 (05) : S346 - S346
  • [30] COMORBIDITY MEASURES TO PREDICT HEALTHCARE COSTS AMONG ELDERLY GYNECOLOGIC CANCER SURVIVORS IN THE US: AN ANALYSIS OF SEER-MEDICARE DATA
    Park, C.
    Lawson, K. A.
    Barner, J. C.
    Powers, D. A.
    Rascati, K. L.
    Wilson, J. P.
    VALUE IN HEALTH, 2017, 20 (05) : A103 - A103